Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
24 results
D3.17 - Outcomes of Anti-Tuberculosis Drug Reintroduction Following Adverse Drug Reactions among Adult Patients at a Tertiary Hospital in the Philippines (2022-2024)
D3.27 - Nivolumab-Induced Psoriasiform Eruption: Diagnostic Challenge Between Immune-Related Toxicity and Drug Allergy
D3.30 - Automated generation of structured clinical databases in drug hypersensitivity: real-world validation in patients with proton pump inhibitor reactions
D3.16 - Increase of Post–SARS-CoV-2 Rashes Mimicking Penicillin Allergy in Children with Group A beta-hemolytic Streptococcus Infection: an emerging and challenging issue
D3.18 - Role of an Allergological Work-up in Antibiotic Allergy Delabeling in Mexican Pediatric Patients
D3.20 - Study of “in vitro” cross reactivity between nsLTP’s comparing “in silico” results with a new specific IgE test based on immunoblot methodology
D3.21 - When the Patient Diagnoses Herself: Amoxicillin-Induced Acute Pancreatitis as a Rare Manifestation of Drug Hypersensitivity
D3.25 - Machine learning models to differentiate cross-reactive and selective-hypersensitive patients to nonsteroidal anti-inflammatory drugs hypersensitivity
D3.31 - Real-world Practices in the Diagnosis and Evaluation of Allergic Rhinitis among Korean Specialists
D3.28 - Effectiveness of the Hypoallergenic Home Visit Program in Treating Moderate-to-Severe Allergic Rhinitis: An Environmental Control Study in Southern China
D3.29 - China's First Three-Dimensional Indoor Dust Mite Allergen Distribution Map: A Cross-Sectional Study of Dust Mite-Allergic Patients in Guangzhou
D3.32 - China's Hypoallergenic Home Visit Program: A Standardized Process for Environmental Control Based on a Mobile Application
D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study
D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study
D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study
D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial
D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial
D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial
D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort
D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download